Zinc pyrithione is a potent inhibitor of PL Pro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication아연 피리티온은 SARS-CoV-2 진입 및 복제를 생체 외에서 억제하는 PL Pro 및 카텝신 L 효소의 강력한 억제제입니다.Article Published on 2022-12-012022-09-11 Journal: Journal of Enzyme Inhibition and Medicinal Chemist [Category] COVID19(2023년), SARS, 치료제, [키워드] analogue Anti-SARS-CoV-2 Activity Antiviral antiviral activity Antiviral agents assays cathepsin L comparable complex complexes contrary COVID-19 effective enzyme Enzymes evaluated Ex vivo expressed human lung tissue in vitro inhibition inhibitor involved Ligand media Pro pyrithione Replication ruthenium SARS-CoV-2 SARS-CoV-2 entry stability synthesised therapeutic therapeutic agent Zinc Zinc complexes Zinc pyrithione [DOI] 10.1080/14756366.2022.2108417 PMC 바로가기 [Article Type] Article
Molecular interactions and inhibition of the SARS-CoV-2 main protease by a thiadiazolidinone derivativeArticle Published on 2022-11-012022-11-15 Journal: Proteins [Category] COVID19(2023년), SARS, 치료제, [키워드] comparable conformational docking enzyme inhibitor Interaction involved Local main protease molecular molecular dynamics Molecular dynamics simulation molecular interaction Pro probe protease protocol SARS-CoV-2 the SARS-CoV-2 thiadiazolidinone. viral life cycle [DOI] 10.1002/prot.26385 PMC 바로가기
Derivation, Functionalization of (S)-Goniothalamin from Goniothalamus wightii and Their Derivative Targets SARS-CoV-2 MPro, SPro, and RdRp: A Pharmacological PerspectiveArticle Published on 2022-10-172022-11-15 Journal: Molecules [Category] COVID19(2023년), SARS, 치료제, [키워드] (S)-Goniothalamin Anti-viral anticancer antioxidant antiviral properties antiviral property approach characterization complex Compound coronavirus COVID-19 derivation derivative disease drug examined LC-MS molecular molecular dynamics MPro NMR pandemic performed phytochemical platform Pro RdRP required Research SARS-CoV-2 SARS-COV-2 infection Simulation study spike glycoprotein target target protein threat [DOI] 10.3390/molecules27206962 PMC 바로가기
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antiviralsSARS-CoV-2 항바이러스제로서의 보세프레비르 기반 주요 프로테아제 억제제의 체계적인 탐색Article Published on 2022-10-052022-09-11 Journal: European journal of medicinal chemistry [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] 293T cell 293T cells active site Alanine aldehyde amide Antiviral antiviral potency boceprevir Carbamate carbamide changed characterized complex covalent inhibitor COVID-19 crystal structure crystal structures cysteine cytotoxicity expressed HCV hydrophobic hydrophobic interaction IMPROVE in vitro inhibit inhibitor inhibitors isovaleramide M pro main protease Modification modifications N-terminal nitrile observation Opal PF-07321332 Pro protease Protease inhibitor recognize residue reversed SARS-CoV-2 SARS-CoV-2 main protease SARS-CoV-2 variants side chain substrate tested the SARS-CoV-2 undetectable unique warhead [DOI] 10.1016/j.ejmech.2022.114596 PMC 바로가기 [Article Type] Article
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antiviralsSARS-CoV-2 항바이러스제로서의 알데히드 기반 트리펩티딜 주요 프로테아제 억제제의 다각적 평가Article Published on 2022-10-052022-09-11 Journal: European journal of medicinal chemistry [Category] COVID19(2023년), SARS, 치료제, [키워드] 293T cell 293T cells active site aldehyde Amino acid amino acids Antiviral antiviral potency binding carbon cellular complexes conducted covalent inhibitors COVID-19 crystal structure cysteine cytotoxicity develop enzyme exhibited expressed flexible high potency in vitro inhibit inhibitor inhibitors interact low potency M pro main protease N-terminal pathogen Previous studies previous study Pro protease Protease inhibitor residue residues SARS-CoV-2 selected Structural variation structures tolerable Toxicity Treatment treatment of COVID-19 Tripeptides. unnatural Variation X-ray [DOI] 10.1016/j.ejmech.2022.114570 PMC 바로가기 [Article Type] Article
The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate강력한 항바이러스 약물 후보로서 SARS-CoV-2 3C 유사 프로테아제에 대한 펩티도미메틱 억제제의 구조 기반 설계Article Published on 2022-08-052022-09-11 Journal: European journal of medicinal chemistry [Category] COVID19(2023년), SARS, 치료제, [키워드] 3C Like protease 3CL 3CL pro acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-SARS-CoV-2 Anti-viral anti-viral drug applied complexes Compound coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 deficiency described develop drug candidates effective inhibit inhibitor inhibitors inhibitory activity Like Medicine pathogen Peptidomimetic inhibitors potent Prevent Pro protease Protease inhibitor protein-ligand respiratory SARS-CoV-2 screened Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus structure-based design targeting the SARS-CoV-2 Transcription treat viral replication X-ray [DOI] 10.1016/j.ejmech.2022.114458 PMC 바로가기 [Article Type] Article
Luminescent Assay for the Screening of SARS-CoV-2 M Pro InhibitorsSARS-CoV-2 M Pro 억제제의 스크리닝을 위한 발광 분석Article Published on 2022-08-032022-09-11 Journal: Chembiochem [Category] COVID19(2023년), SARS, 치료제, [키워드] antiviral drug can be used cleavage site Enzymes exhibit imaging agents in viral Infection inhibitor inhibitors Luminescence luminescence. M pro outbreak peptide Pro probe protease Replication reported SARS-CoV-2 Screening viral replication [DOI] 10.1002/cbic.202200190 PMC 바로가기 [Article Type] Article
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of NirmatrelvirNirmatrelvir의 잠재적인 SARS-CoV-2 회피에 대한 진화적 및 구조적 통찰력Review Published on 2022-07-142022-09-11 Journal: Journal of medicinal chemistry [Category] COVID19(2023년), SARS, 변종, [키워드] Analysis analyzed antibody approval arises broad-spectrum antiviral broad-spectrum antivirals combination therapy COVID-19 pandemic drug-resistant indicate inhibitor insight M pro Mutation Nirmatrelvir Paxlovid Potential Pro protease residue residues Ritonavir SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants significantly U.S. FDA Vaccine Viral resistance viral variant [DOI] 10.1021/acs.jmedchem.2c00404 PMC 바로가기 [Article Type] Review
Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary Outcomes of Randomized controlled trialShort communication Published on 2022-05-012022-10-05 Journal: Journal of Ayurveda and Integrative Medicine [Category] 신약개발, 임상, [키워드] Ayurveda BNP breathlessness clinical trial coagulative complement Complication control group Controlled trial cough COVID-19 COVID-19 disease creatinine phosphokinase CRP disease Diseases fatigue Hospital stay ICU infective Inflammatory marker integrative medicine intervention group Madhav Rasayan plus management marker Moderate COVID-19 organ outcome parallel group patients patients with moderate Pro Quality of life Randomized controlled trial reduced restored reveal severity significantly standard care statistically significant reduction supplemental oxygen symptoms of COVID-19 Tablet tissue Treatment was reduced [DOI] 10.1016/j.jaim.2022.100590 [Article Type] Short communication
Systems pharmacology-based drug discovery and active mechanism of natural products for coronavirus pneumonia (COVID-19): An example using flavonoidsResearch article Published on 2022-04-012022-10-05 Journal: Computers in biology and medicine [Category] 치료제, [키워드] 3CL ABC Analysis Anti-inflammatory Antiviral antiviral effects Combination complex component Compound Coronavirus pneumonia COVID-19 demonstrated drug Drug discovery Drug screening EGCG EGFR Epigallocatechin-3-gallate example flavonoids functions immune responses Inflammatory KEGG KEGG pathway Kyoto Luteolin mechanism mechanism of action mechanisms molecular docking natural natural products NOS Ontology pathway enrichment pharmacological PPI Prevent Pro Protein protein-protein interaction quercetin resource Result second selected selective stability System Systems pharmacology target targets tissue injury treat Treatment was performed [DOI] 10.1016/j.compbiomed.2022.105241 [Article Type] Research article